Moisturizing body milk as a reservoir of Burkholderia cepacia: outbreak of nosocomial infection in a multidisciplinary intensive care unit by Álvarez-Lerma, Francisco et al.
Open Access
Available online http://ccforum.com/content/12/1/R10
Page 1 of 6
(page number not for citation purposes)
Vol 12 No 1 Research
Moisturizing body milk as a reservoir of Burkholderia cepacia: 
outbreak of nosocomial infection in a multidisciplinary intensive 
care unit
Francisco Álvarez-Lerma1, Elena Maull1, Roser Terradas1, Concepción Segura2, Irene Planells3, 
Pere Coll4, Hernando Knobel1 and Antonia Vázquez1
1Services of Intensive Care Medicine, Evaluation and Clinical Epidemiology, and Internal Medicine and Infectious Diseases, Hospital Universitari del 
Mar, Universitat Autònoma de Barcelona, Passeig Marítim 25-29, E-08003 Barcelona, Spain
2Service of Infectious Pathology, Laboratori de Referència de Catalunya, C/Selva 10, edifice INBLAU A, Parc de Negocis Mas Blau, E-08820 El Prat 
de Llobregat, Barcelona, Spain
3Service of Clinical Microbiology, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Passeig Vall d'Hebron 119-129, E-08035 Barcelona, 
Spain
4Service of Clinical Microbiology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, C/Sant Antoni Maria Claret 167, E-08025 
Barcelona, Spain
Corresponding author: Francisco Álvarez-Lerma, Falvarez@imas.imim.es
Received: 25 May 2007 Revisions requested: 3 Jul 2007 Revisions received: 16 Sep 2007 Published: 31 Jan 2008
Critical Care 2008, 12:R10 (doi:10.1186/cc6778)
This article is online at: http://ccforum.com/content/12/1/R10
© 2008 Álvarez-Lerma et al.; licensee BioMed Central Ltd. 
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Background An outbreak of severe nosocomial Burkholderia
cepacia infections in patients admitted to intensive care unit
(ICU), including investigation of the reservoir, is described.
Methods Over a period of 18 days, isolates of Burkholderia
cepacia were recovered from different biological samples from
five patients who were admitted to a multidisciplinary 18-bed
intensive care unit. Isolation of B. cepacia was associated with
bacteraemia in three cases, lower respiratory tract infection in
one and urinary tract infection in one. Contact isolation
measures were instituted; new samples from the index patients
and adjacent patients were collected; and samples of
antiseptics, eau de Cologne and moisturizing body milk available
in treatment carts at that time were collected and cultured.
Results  B. cepacia was isolated from three samples of the
moisturizing body milk that had been applied to the patients.
Three new hermetically closed units, from three different
batches, were sent for culture; two of these were positive as
well. All strains recovered from environmental and biological
samples were identified as belonging to the same clone by
pulsed-field gel electrophoresis. The cream was withdrawn from
all hospitalization units and no new cases of B. cepacia infection
developed.
Conclusion Moisturizing body milk is a potential source of
infection. In severely ill patients, the presence of bacteria in
cosmetic products, even within accepted limits, may lead to
severe life-threatening infections.
Introduction
Burkholderia cepacia is a nonfermenting Gram-negative aero-
bic bacillus that was until recently considered an opportunistic
pathogen in oncological patients or in those with cystic fibro-
sis. This pathogen is associated with low morbidity and mor-
tality despite high intrinsic resistance to numerous
antimicrobial and antiseptic agents [1]. It is characterized by a
capacity to survive in a large variety of hospital microenviron-
ments, resulting in its dissemination via contaminated respira-
tory equipment, disinfectants, blood analyzers and running
water supply [2-5]. In intensive care units (ICUs) outbreaks of
B. cepacia in association with contaminated nebulizers [6],
indigo-carmine dye in patients with nasogastric tubes [7], or
mouth washings [8] have been reported.
Simultaneous detection of several isolations of this pathogen
in the same service heralds the occurrence of an epidemic out-
break associated with a reservoir. Under such these circum-
stances it is advisable that an epidemiological study be
conducted to identify the origin of the infection and the
ICU = intensive care unit; PFGE = ulsed field gel electrophoresis.Critical Care    Vol 12 No 1    Álvarez-Lerma et al.
Page 2 of 6
(page number not for citation purposes)
epidemiological chain. Here we describe an outbreak of epi-
sodes of severe infection caused by B. cepacia in a multidis-
ciplinary Spanish ICU in which contaminated moisturizing
body milk served as the reservoir and origin of the infection.
Elimination of the reservoir was associated with eradication of
B. cepacia from the hospital.
Materials and methods
Description of the ICU
Our institution is a 450-bed tertiary care teaching hospital in
the city of Barcelona, Spain. The multidisciplinary ICU includes
18 beds in a semicircular distribution, with independent rooms
that may be isolated by transparent glass doors. Rooms are
equipped with individual sinks and dispensers of alcohol solu-
tion for cleansing of the hands without water. Six of the rooms
have an independent air extraction system. The nursing staff
includes one nurse for each two beds in all shifts and one cer-
tified nurse assistant for each five beds in all shifts. All person-
nel have received basic training for the invasive procedures
that they perform, and written protocols for each procedure
are available. Overall, patients are admitted to the ICU
because of medical complications (45%) and ischaemic heart
disease (35%), with a lower percentage of elective surgical
patients (10%) and polytrauma patients (10%). In 2006, the
mean (± standard deviation) Acute Physiology and Chronic
Health Evaluation II score was 10.6 ± 6.5, and the mean
length of ICU stay was 7.9 ± 8.3 days. Patients were mechan-
ically ventilated for 47% of ICU days and had a urinary catheter
for 75% of days.
The ICU participates annually in a national surveillance pro-
gramme for nosocomial infections. In the year 2006, the rate
of nosocomial infections related to invasive devices was 16.6
per 1,000 days of ICU stay (50th percentile for the national
study, which was 15.1 per 1,000 days of ICU stay). In previous
years no case of infection with B. cepacia in the ICU has been
registered. Also, as part of the hospital surveillance pro-
gramme for multiresistant pathogens, weekly surveillance cul-
tures from patients at risk for multiresistant pathogens (ICU
stay >7 days, use of broad-spectrum antibiotics, and use or
two or more invasive devices) are carried out; during the 24
months preceding the outbreak, B. cepacia had not been iden-
tified in these samples.
Description of the outbreak
The index cases were those patients in whom B. cepacia was
isolated in one or more biological samples. B. cepacia isolates
were classified as colonization or infection. The US Centers
for Disease Control and Prevention definitions for nosocomial
infections [9] were used. 'Outbreak' was defined as the simul-
taneous presence of four patients admitted to the ICU with
positive cultures for B. cepacia (a further patient was later
identified). The outbreak was detected through routine infec-
tion control surveillance.
In all cases, B. cepacia strains were isolated from clinical sam-
ples in standard culture media. Identification was performed
using the biochemical tests MicroScan® (Dade-Behring, West
Sacramento, CA, USA) and API System (BioMerieux, Marcy
l'Etoile, France). Microdilution (panel NC38, MicroScan®) and
disk diffusion techniques were used for antibiotic susceptibil-
ity testing. New samples from the index patients and adjacent
patients at greater risk for cross-transmission, including
oropharyngeal mucosa, urine and bronchial aspirate samples,
were collected. Samples of the antiseptic (iodine solution,
70% isopropyl alcohol and chlorhexidine), eau de Cologne
and moisturizing body milk available in the treatment carts at
that time were also collected and sent to the Laboratory of the
Service of Microbiology (Unit of Food and Environmental
Microbiology) of the Hospital Vall d'Hebron in Barcelona.
These samples were cultured using the following media: blood
agar, MacConkey agar, brain heart infusion agar, brain heart
infusion agar supplemented with Tween 80, and liquid and
solid media for anaerobic micro-organisms. The Vitek 2 system
(BioMerieux) was used in the identification of the different
pathogens. Strains isolated from environmental samples were
frozen and, together with strains recovered from biological
samples, were sent to the laboratory of microbiology of Hospi-
tal Santa Creu i Sant Pau, in Barcelona, for subsequent molec-
ular typing by immunoelectrophoretic methods. Pulsed field
gel electrophoresis (PFGE) of chromosomal DNA digested
with Spel was performed using Chef DRIII System apparatus
(Bio-Rad, Richmond, CA, USA), under conditions appropriate
for the enzyme. Lambda ladder PFGE marker (New England
Biolabs, Beverley, MA, USA) was used as the standard
marker. Analysis of PFGE profiles was conducted using the
software Bio Image Whole Band Analyzer (Genomic Solu-
tions, Ann Arbor, MI, USA).
The Committee of Infections of the hospital was notified of the
occurrence of the outbreak. Informed consent from patients
was not required because investigation of the outbreak, isola-
tion measures and detection of the source of infection did not
involve interventions other than those routinely performed in
the care of patients under these circumstances.
In accordance with official recommendations of the govern-
ment of Catalonia [10] and following the protocol imple-
mented in the hospital, contact isolation measures were
instituted. These included assigning patients to their own
room, handwashing on entry and exit (with soap and water,
and alcohol disinfection), use of disposable gowns and gloves,
use of clinical materials exclusively for the patient (stetho-
scope and pulse oximeter) and visiting restrictions. Cleaning
measures in the rooms were intensified, including use of sin-
gle-use material or materials exclusive to each patient. Patients
with local signs of infection and/or inflammatory systemic
response were given one or more antibiotics, depending on
results of antibiotic susceptibility testing. Every effort was
made to increase universal precautions to avoid cross-trans-Available online http://ccforum.com/content/12/1/R10
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mission of micro-organisms, especially hand washing and use
of alcohol solutions.
Results
During a period of 18 days in August 2006, five patients admit-
ted to a multidisciplinary ICU were identified in whom one or
more strains of B. cepacia, with identical pattern of antibiotic
susceptibility (sensitivity to ciprofloxacin, meropenem, pipera-
cillin-tazobactam and co-trimoxazole; resistance to aminogly-
cosides, cephalosporin, imipenem, penicillins and aztreonam),
were recovered from different biological samples. The individ-
ual details for each patient, including date of admission to the
hospital, date of admission to the ICU and recovery of the first
sample in which B. cepacia was isolated, are shown in Table
1. In four patients specimens were obtained in the ICU,
whereas in the remaining patient the pathogen was isolated in
a urine sample collected before ICU admission.
Isolation of B. cepacia was associated with bacteraemia in
three patients, lower respiratory tract infection in one and uri-
nary tract infection in one. The cause of bacteraemia was
attributed to a respiratory source in one case and to a central
venous catheter in one; the remaining case was considered a
primary bacteraemia. In three patients, new B. cepacia strains
were isolated in control samples (on two occasions from the
same tracheal aspirate samples as the original specimen, and
in one patient, with initial positive samples from a central
venous catheter and peripheral blood, B. cepacia was later
isolated from urine samples). In the two patients with B. cepa-
cia  recovered from tracheal aspirate samples, the infective
strain persisted despite directed antibiotic treatment. In one of
these patients, B. cepacia along with Pseudomonas aerugi-
nosa were isolated in blood cultures 2 weeks later, and in
another patient from a central venous catheter tip and pharyn-
geal swab. Finally, another patient with initial urinary tract
infection exhibited mixed bacteremia (B. cepacia and P. aeru-
ginosa) in the final stage of the clinical course. Surveillance
samples drawn from adjacent patients with an artificial airway
were negative for the epidemic strain.
In order to assess whether moisturizer had been contaminated
before or after opening of the jar, three new hermetically
closed units stored in the hospital pharmacy service or in the
ICU, from three different batches (one of them coinciding with
that analyzed in the ICU), were sent for culture. In samples
obtained from two moisturizing body milk units – one belong-
ing to the batch from which the initial isolation of the micro-
organism has been obtained – B. cepacia strains were iso-
lated (Table 2). Quantitative data regarding contamination of
the moisturizing body milk were not obtained. Strains isolated
Table 1
Characteristics of patients and their evolution since hospital admission until B cepacia isolation and ICU discharge
Data Study patients
12345
A g e  ( y e a r s ) 7 87 57 88 57 1
Diagnosis Peritonitis Heat stroke Heat stroke Urinary septic shock Peritonitis and 
cardiac arrest
Hospital admission 14 July 2006 28 July 2006 26 July 2006 3 August 2006 11 July 2006
ICU admission 15 July 2006 28 July 2006 26 July 2006 8 August 2006 21 August 2006
B cepacia isolation 1 August 2006 3 August 2006 12 August 2006 12 August 2006 18 August 2006
Sample 1 TAa TA CVC/skin AC/blood Urine
Sample 2 TAa (5 August 2006) TAa (5 August 2006) Urine (14 August 
2006)
Urine (15 August 
2006)
CVC/Blood, urine (12 
September 2006)
Sample 3 TAa (18 August 2006) TAa (16 August 2006) - - -
Sample 4 TAa (20 August 2006) TAa (21 August 2006) - - -





ICU discharge 9 September 2006 28 August 2006 18 September 2006 23 August 2006 17 September 2006
Cause of death MOF Encephalopathy Alive Alive Encephalopathy
B. cepacia Related 
death
No No No
aTogether with one or more micro-organisms. AC, arterial catheter; CVC, central venous catheter; ICU, intensive care unit; MOF, multiple organ 
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Figure 1
PFGE pattern of Burkholderia cepacia isolates in body milk and biological samples PFGE pattern of Burkholderia cepacia isolates in body milk and biological samples. MK, molecular weight marker.
Table 2
Results of cultures of ICU environmental samples (fluids)
Sample Result
Phase I study (16 August 2006)
Iodine solution (cart A: open) Negative
Iodine solution (cart B: open) Negative
Eau de Cologne (cart A: open) Negative
Eau de Cologne (cart B: open) Negative
Eau de Cologne (cart C: open) Negative
Moisturizing body milk (cart A: open): batch 527.05–06 Burkholderia cepacia
Moisturizing body milk (cart B: open): batch 527.05–06 Burkholderia cepacia
Moisturizing body milk (cart C: open): batch 527.05–06 Burkholderia cepacia
Phase II study (25 August 2006)
Moisturizing body milk (ICU: closed): batch 527.05.06 Burkholderia cepacia
Moisturizing body milk (pharmacy: closed): batch 512.07.06 Burkholderia cepacia
Moisturizing body milk (ICU: closed): batch 525.03–06 Negative
ICU, intensive care unit.Available online http://ccforum.com/content/12/1/R10
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from environmental and biological samples were identified as
belonging to the same clone by PFGE (Figure 1).
Once it was suspected that the moisturizer was the source of
the outbreak the cream was withdrawn from the ICU (23
August 2006), and when samples from closed units were pos-
itive for the same pathogen by molecular typing (3 September
2006) the cream was withdrawn from all hospitalization units.
Notification was immediately sent to the manufacturer and the
Ministry of Health and Consumption. No new cases of B.
cepacia infection occurred in the hospital.
Discussion
The main contribution of the present study is the identification
of a new reservoir of nosocomial pathogens, in this case B.
cepacia in the moisturizing body milk used in the care of bed-
ridden ICU patients. In this case, the epidemiological chain
began with contamination of the lotion during manufacturing,
transportation, or storing stages before application of moistur-
izing body milk to patients. Then, the hands of nursing person-
nel transmitted the pathogen to patients, in whom
contamination of inert devices (catheters or tubes) or direct
administration (skin, wounds, or airways) was responsible for
severe nosocomial infection.
The implementation in our hospital of continuous control of
pathogens of significance, among which nonfermenting Gram-
negative bacilli are included, allowed us not only to detect the
outbreak promptly but also to study environmental samples,
facilitating the identification and elimination of the reservoir.
The standard procedure for study of an epidemic outbreak in
our hospital is based on a case-control study. In the present
case, however, samples of various products routinely used in
the care of ICU patients were analyzed. Suspicion was based
on the fact that infected patients did not occupy adjacent beds
and that use of products found in treatment carts at the time
of the outbreak was a characteristic common to all affected
patients. In nonbiological samples, B. cepacia was isolated in
three samples of the moisturizing body milk that was applied
to the patients and available for use in ICU treatment carts. In
other nonbiological samples sent for culture, no pathogens
were isolated.
Topical products for skin care are not required to be sterilized
[10]. The microbiological quality of these products is regulated
by the European Pharmacopoeia, topical products (category
II: nonsterile), which indicates that topical products should not
contain more than 102 aerobic bacteria or moulds, and no
more than 101 enterobacteria per gram or millilitre, as well as
complete absence of P. aeruginosa and  Staphylococcus
aureus. In the outbreak reported here, no quantitative studies
were performed but growth of forbidden species was not
detected. B. cepacia is a nonfermenting Gram-negative bacil-
lus equal to P. aeruginosa, so that presumably no strains of
this pathogen would have been detected.
It has traditionally been suggested that the appearance of mul-
tiresistant pathogens is related to the use of broad-spectrum
antibiotics over prolonged periods of time. Although in most
cases this is the main mechanism of selection, in the cases
reported here B cepacia was acquired from an exogenous
source from an external reservoir introduced into the ICU.
Intrinsic contamination of nasal sprays [5,11,12] and disinfect-
ants [8] with B. cepacia has previously been documented, but
the outbreak reported here is the first observation of B. cepa-
cia  infection secondary to contamination of a cosmetic
product.
Accumulation of colonized and/or infected patients in the ICU
despite distribution of the contaminated batch of the body milk
throughout the hospital wards may be accounted for by two
factors. First, maintenance of good body hygiene in ICU
patients is carried out in the patient's own bed, and it is com-
mon practice to apply moisturizers after each manoeuvre that
involves washing of cutaneous surfaces, so that a greater inoc-
ulum is obtained as compared with any other patients hospital-
ized in the wards. Second, because the number of samples
from ICU patients submitted for culture – including surveil-
lance samples – is much greater than for non-ICU patients, the
probability of detection is also greater.
In most occasions in which products of common use are
applied to patients (creams, antiseptic solutions, and so on),
contamination and development of a reservoir results from
handling of these products by health care personnel. In the
present outbreak, however, contamination of the moisturizer
occurred during the manufacturing process.
Conclusion
An outbreak of B. cepacia infection in a multidisciplinary ICU
was detected because of a well functioning hospital surveil-
lance system for multiresistant pathogens. This outbreak of
nosocomial infection caused by B. cepacia in five severely ill
patients, in which moisturizing body milk was the reservoir of
the causative pathogen, supports a strong recommendation
not to use cosmetic products for which there is no guarantee
of sterilization during the manufacturing process.
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Key messages
￿  Simultaneous identification of five ICU patients with 
infections caused by B. cepacia suggested the occur-
rence of an epidemic outbreak; a surveillance system 
for identification of multiresistant pathogens facilitated 
recognition of cases.
￿  The study of environmental samples allowed identifica-
tion of the moisturizing body milk used in the patients' 
care as the reservoir of B. cepacia.
￿  All strains recovered from environmental and biological 
samples were identified as belonging to the same clone 
by PFGE.
￿  Contamination of the moisturizer occurred during the 
manufacturing process.
￿  Products used in the daily hygiene of critically ill 
patients should be sterile.